Skip to content
Company Analysis

Molecular Partners AG MOLN

A comprehensive view of key metrics, scores, and financial health for Molecular Partners AG

Overview of Molecular Partners AG

MOLN NMS
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Micro Cap
Molecular Partners AG (MOLN), is a Micro Cap company, in the Biotechnology industry, last closed at $3.71, about 0.0% overvalued vs fair value, +2.1% 1Y return, ranked 972/1145 in sector.
Metrics Rev Growth -100.0% ROE -55.6%
USD 3.71
-2.60%
(Delayed)
• Vol 90d: 48.1%
52-Week Range
Market Cap
$138.54M
Enterprise Value
$56.19M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Weak
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Weak
Valuation
Fair
Completeness: 76%
Confidence: 89%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.molecularpartners....
HQ Schlieren
Employees 158
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data
Show more details
  • Revenue data missing or non-positive

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
CHF 82.7M
29.4%%
Total Revenue
CHF 0
-100%%
Net Income
-CHF 61.7M
-14.1%%
Operating Expense
CHF 55.4M
-16.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
19.4 months
Good

Adequate runway, but financing may be needed within 18 months

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Molecular Partners AG's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
33
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.76), providing operational cushion.

Key risks

  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.12), suggesting weak customer stickiness.
  • Scale Without Profitability Despite scale, profitability lags peers (score 0.22), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
30
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 60% Coverage
Trade-Off Triangle Visualization A ternary plot showing MOLN's balance between Growth (16.6%), Profitability (26.5%), and Safety (56.9%). Growth 17% Safety 57% Profitability 27%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

20th percentile vs peers
21
Key Signals
TSR -65.8% 20p
Strengths
  • Current Ratio in top 20% of peers (8.79, 81th percentile)
  • Strong liquidity position vs peers
Risks
  • Growth in bottom 20% of peers (percentile: 20)

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

71th percentile vs peers
72
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Molecular Partners AG.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000